- Conditions
- Sarcoidosis
- Interventions
- d-methylphenidate
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 26
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- ADHD
- Interventions
- Focalin XR
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- ADHD, ADD
- Interventions
- Dexmethylphenidate HCl extended-release capsules
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 252 participants
- Timeline
- 2006
- U.S. locations
- 25
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
- Interventions
- methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
- Drug · Other
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
- Conditions
- ADHD
- Interventions
- KP415 oral capsule
- Drug
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Bradenton, Florida + 15 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Problem Behavior
- Interventions
- Stimulant
- Drug
- Lead sponsor
- Matthew J O'Brien, PhD, BCBA-D
- Other
- Eligibility
- 48 Months to 12 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Dexmethylphenidate
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- ADHD
- Interventions
- Focalin XR
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
- Interventions
- ADHD Medication, Omega-3 Fatty Acids
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
- Interventions
- ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Guanfacine (GUA), Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Drug Binding to DAT Receptors
- Interventions
- dex-methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
- Interventions
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Guanfacine, Methylphenidate (MPH)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Northbrook, Illinois
- Conditions
- ADHD
- Interventions
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- ADHD
- Interventions
- KP415 oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more